PZ0322

WAY 170523

≥98% (HPLC)

• Sinónimos: N-[2-[4-[[[2-[(Hydroxyamino)carbonyl]-4,6-dimethylphenyl](phenylmethyl)amino]sulfonyl]phenoxy]ethyl]-2-benzofurancarboxamide, WAY170523
• Fórmula empírica (notación de Hill): C₃₃H₃₁N₃O₇S
• Número de CAS: 307002-73-9
• Peso molecular: 613.68
• MDL number: MFCD09753279
• UNSPSC Code: 51111800
• PubChem Substance ID: 329823839
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 25 mg/mL, clear
• storage temp.: room temp
• SMILES string: O=S(N(CC1=CC=CC=C1)C2=C(C(NO)=O)C=C(C)C=C2C)(C3=CC=C(OCCNC(C4=CC5=C(C=CC=C5)O4)=O)C=C3)=O
• InChI: 1S/C33H31N3O7S/c1-22-18-23(2)31(28(19-22)32(37)35-39)36(21-24-8-4-3-5-9-24)44(40,41)27-14-12-26(13-15-27)42-17-16-34-33(38)30-20-25-10-6-7-11-29(25)43-30/h3-15,18-20,39H,16-17,21H2,1-2H3,(H,34,38)(H,35,37)
• InChI key: FARMEEAGJWMFSZ-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

WAY 170523 is a potent and selective inhibitor of matrix metalloprotease MMP-13 (Collagenase-3), expressed in the skeleton during embryonic development, and sometimes highly overexpressed in human carcinomas and in chondrocytes and synovial cells in rheumatoid arthritis and osteoarthritis. Mutations in the MMP-13 gene has been shown to cause metaphyseal anadysplasia (MANDP). WAY 170523 has an IC₅₀ of 17 nM for MMP-13 and showed >5800-, 56-, and >500-fold selectivity against MMP-1, MMP-9, and TACE (TNFα converting enzyme), respectively.

Other Notes

This compound was developed by Pfizer for Cytoskeleton & Extracellular Matrix research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Legal Information

Sold for research purposes under agreement from Pfizer Inc.

Información de seguridad

• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 3